Article Information
History
- March 14, 2022.
Article Versions
- You are currently viewing Version 1 of this article (March 14, 2022 - 12:37).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- I. Pediaditakis1,9,†,*,
- K. R. Kodella1,2,†,
- D. V. Manatakis1,
- C. Y. Le1,
- S. Barthakur1,
- A. Sorets1,
- A. Gravanis2,
- L. Ewart1,
- L. L. Rubin3,4,5,
- E. S. Manolakos6,7,
- C. D. Hinojosa1 and
- K. Karalis1,8,10,*
- 1Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA
- 2University of Crete Medical School, Department of Pharmacology, Heraklion, 71110 Greece
- 3Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA
- 4Harvard Stem Cell Institute, Cambridge, MA, USA
- 5Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA
- 6Department of Informatics and Telecommunications, National and Kapodistrian University of Athens, Greece
- 7Northeastern University, Bouvé College of Health Sciences, Boston, MA, USA
- 8Endocrine Division, Children’s Hospital, Harvard Medical School, Boston, MA, USA
- 9Vesalius Therapeutics Inc., 100 Binney St, Cambridge, MA, 02142, USA
- 10Regeneron Pharmaceuticals, 777 Old Saw Mill River Rd, Tarrytown, NY, 10591, USA
- ↵*Corresponding authors: spediaditakis{at}vesaliustx.com, katia.karalis{at}regeneron.com
↵† These authors contributed equally